Health
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from a clinician survey highlighting the functional impact experienced by patients with mild tardive dyskinesia (TD) severity and the impact of treatment with INGREZZA® (valbenazine) capsules in a real-world setting. In a subgroup analysis, nearly all patients with clinician-reported mild TD treated with INGREZZA experienced fewer uncontrolled movements, with most demonstrating symptom improvement within fou
About this update from Neurocrine Biosciences, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Clinician survey showed 90% of patients with mild tardive dyskinesia experienced emotional, social or physical impairment","length":121,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":121,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Following initiation of INGREZZA, 96% of patients with mild tardive dyskinesia showed clinician-reported improvement in uncontrolled movements; of those patients, 86% improved within 4 weeks","length":190,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":190,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Reductions in involuntary movements with INGREZZA treatment were associated with improvements in overall functional status, independence, activities of daily living and ability to work","length":184,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":184,"olType":false},{"type":"text","content":"SAN DIEGO, May 18, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from a clinician survey highlighting the functional impact experienced by patients with mild tardive dyskinesia (TD) severity and the impact of treatment with INGREZZA® (valbenazine) capsules in a real-world setting. In a subgroup analysis, nearly all patients with clinician-reported mild TD treated with INGREZZA experienced fewer uncontrolled movements, with most demonstrating symptom improvement within four weeks. Patients also showed widespread improvements in functional status, independence, ability to perform daily activities and ability to work. The findings are being presented at the American Psychiatric Association 2026 Annual Meeting, taking place May 16-20 in San Francisco.","length":836,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Neurocrine Biosciences, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Neurocrine Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":74,"url":"https://media.zenfs.com/en/prnewswire.com/9adfb0c84e7d306b48de2742f62d85d4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tmdenVtXM7LFmbrt7BNiag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzMA--/https://media.zenfs.com/en/prnewswire.com/9adfb0c84e7d306b48de2742f62d85d4","width":400,"height":74},"...